 |
|
Scripps research scientists develop innovative dual action anthrax vaccine-antitoxin combination
October 05, 2007New compound could provide rapid treatment and long-term protection in a single injection
The immune response generated in rats by the new agent protects against lethal toxin exposure after only one injection, and is faster and stronger than any currently available vaccine.
The new study, led by Scripps Research scientists Anette Schneemann and Marianne Manchester, and Salk Institute Professor John A.T. Young, was published in the October 5 issue of the journal PLoS Pathogens (Volume 3, Issue 10).
"The new anti-anthrax agent that we developed is an important and potentially critical development for anyone who works with the bacterium or those who might be exposed to it in a bioterrorism attack," Schneemann said. "While other strategies are being pursued to develop improved anthrax vaccines, none of these offer the distinct advantage of combining the function of a vaccine with a potent antitoxin."
Concerns about anthrax-a potentially fatal disease caused by the spore-forming, gram-positive bacterium Bacillus anthracis-as a weapon of bioterrorism has prompted increased efforts to develop better antitoxins and vaccines. The current vaccine, which was developed in the 1950s, is safe and effective, but requires multiple injections followed by annual boosters. Current anthrax treatment involves antibiotics such as ciprofloxacin and doxycycline that attack the bacteria but provide no protection against the dangerous toxins secreted by the bacteria.
The new study introduces a highly effective dual-action compound that leapfrogs current efforts to develop a second-generation anthrax vaccine. In the research, the scientists created a "multivalent display," with several sites of attachment for recombinant protective antigen protein (PA), the primary component of the current anthrax vaccine, rather than only one. Virus-like particles coated with PA were found to produce a potent toxin-neutralizing antibody response that protected rats from the lethal anthrax toxin after only a single immunization.
The antitoxin strategy arose from the discovery of the anthrax toxin receptor, ANTXR2, in the Young lab. "The new anti-anthrax agent is based on a multivalent display of ANTXR2 on the surface of an insect virus," explains Schneemann. "Our approach was based on the assumption that a multivalent display of recombinant protective antigen protein would induce a far more potent immune response. That turned out to be correct."
Specifically, the new vaccine-antitoxin combination is based on the multivalent display (180 copies) of the PA-binding von Willebrand A (VWA) domain of the ANTXR2 cellular receptor on the Flock House virus. The chimeric virus-like particle platform, which produces protective immunity and has been shown to be safe, inhibited lethal toxin action in in vitro and in vivo models of anthrax infection.
In fact, rats survived exposure to the toxin four weeks after a single injection of the new double-acting agent. This result suggests an extremely rapid production of neutralizing antibodies without the use of an adjuvant, a secondary agent that helps stimulate the immune system and is often used to increase the vaccine response-key goals for the development of third-generation anthrax vaccines.
In addition to its use against anthrax, Schneemann notes that creating a multivalent platform may also have the potential to work against other infectious agents.
"One important reason for the success of this project is that it arose from the multidisciplinary and highly collaborative efforts of our team of microbiologists, structural biologists, and immunologists," said Manchester, who headed a National Institutes of Health (NIH)-funded program project grant that supported the work.
Scripps Research Institute
"The new anti-anthrax agent that we developed is an important and potentially critical development for anyone who works with the bacterium or those who might be exposed to it in a bioterrorism attack," Schneemann said. "While other strategies are being pursued to develop improved anthrax vaccines, none of these offer the distinct advantage of combining the function of a vaccine with a potent antitoxin."
Concerns about anthrax-a potentially fatal disease caused by the spore-forming, gram-positive bacterium Bacillus anthracis-as a weapon of bioterrorism has prompted increased efforts to develop better antitoxins and vaccines. The current vaccine, which was developed in the 1950s, is safe and effective, but requires multiple injections followed by annual boosters. Current anthrax treatment involves antibiotics such as ciprofloxacin and doxycycline that attack the bacteria but provide no protection against the dangerous toxins secreted by the bacteria.
The new study introduces a highly effective dual-action compound that leapfrogs current efforts to develop a second-generation anthrax vaccine. In the research, the scientists created a "multivalent display," with several sites of attachment for recombinant protective antigen protein (PA), the primary component of the current anthrax vaccine, rather than only one. Virus-like particles coated with PA were found to produce a potent toxin-neutralizing antibody response that protected rats from the lethal anthrax toxin after only a single immunization.
The antitoxin strategy arose from the discovery of the anthrax toxin receptor, ANTXR2, in the Young lab. "The new anti-anthrax agent is based on a multivalent display of ANTXR2 on the surface of an insect virus," explains Schneemann. "Our approach was based on the assumption that a multivalent display of recombinant protective antigen protein would induce a far more potent immune response. That turned out to be correct."
Specifically, the new vaccine-antitoxin combination is based on the multivalent display (180 copies) of the PA-binding von Willebrand A (VWA) domain of the ANTXR2 cellular receptor on the Flock House virus. The chimeric virus-like particle platform, which produces protective immunity and has been shown to be safe, inhibited lethal toxin action in in vitro and in vivo models of anthrax infection.
In fact, rats survived exposure to the toxin four weeks after a single injection of the new double-acting agent. This result suggests an extremely rapid production of neutralizing antibodies without the use of an adjuvant, a secondary agent that helps stimulate the immune system and is often used to increase the vaccine response-key goals for the development of third-generation anthrax vaccines.
In addition to its use against anthrax, Schneemann notes that creating a multivalent platform may also have the potential to work against other infectious agents.
"One important reason for the success of this project is that it arose from the multidisciplinary and highly collaborative efforts of our team of microbiologists, structural biologists, and immunologists," said Manchester, who headed a National Institutes of Health (NIH)-funded program project grant that supported the work.
Scripps Research Institute
Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Drug-eluting Stents Magnetic Resonance Domestic Violence Nerve Cells Child Abuse West Nile Virus Dendritic Cells Chronic Kidney Disease Enzymes Language Milky Way Occupational Therapy Fossil Fuel MicroRNA Liver Fibrosis Amyloid Beta Myocardial Infarction Brain Cancer Stem cells Bone Marrow Risky Behavior Lung Disease Fisheries Ageing Acetylcholine
See More: Science News Tags
Anthrax Current Events and Anthrax News RSSUnexpected discovery can open a new chapter in the fight against tuberculosis
A close relative of the microorganism that causes tuberculosis in humans has been found to form spores.
Genetic switch potential key to new class of antibiotics
Researchers have determined the structure of a key genetic mechanism at work in bacteria, including some that are deadly to humans, in an important step toward the design of a new class of antibiotics.
UI chemists' DNA biosynthesis discovery could lead to better antibiotics
Combating several human pathogens, including some biological warfare agents, may one day become a bit easier thanks to research reported by a University of Iowa chemist and his colleagues in the April 16 issue of the journal Nature.
Scientists discover new chemical reaction for DNA production in bacteria and viruses
A team of researchers has discovered a new chemical reaction for producing one of the four nucleotides, or building blocks, needed to build DNA.
OHSU scientists partner with others to form center aimed at combating infectious diseases
Oregon Health & Science University and the University of Washington, along with a number of partner institutions across the Northwest, have received federal funding to form a regional research center aimed at combating emerging or re-emerging infectious diseases that pose a serious threat to human health.
Novel method predicts impact of a covert anthrax release
A new statistical method that can estimate the origin and time of an aerosolized release of the pathogen causing anthrax, following detection of the first few cases has been developed by researchers from the Medical Research Council (MRC) Centre for Outbreak Analysis and Modelling at Imperial College London in collaboration with the Health Protection Agency's Microbial Risk Assessment group.
Study finds program has improved health agencies' preparedness for bioterror and disease outbreaks
A federal program designed to help metropolitan public health agencies prepare to deliver essential medicines to the public after a large-scale bioterror attack or natural disease outbreak has succeeded in improving the level of readiness, according to a new RAND Corporation study.
Goodbye needle, hello smoothie
Instead of a dreaded injection with a needle, someday getting vaccinated against disease may be as pleasant as drinking a yogurt smoothie.
Scripps research scientists engineer new type of vaccination that provides instant immunity
The experiments, thus far performed only in mice, appear to overcome a major drawback of vaccinations - the lag time of days, or even weeks, that it normally takes for immunity to build against a pathogen.
Good bacteria can be EZ Pass for oral vaccine against anthrax
Researchers at North Carolina State University have discovered that the good bacteria found in dairy products and linked to positive health benefits in the human body might also be an effective vehicle for an oral vaccine that can provide immunity to anthrax exposure.
More Anthrax Current Events and Anthrax News Articles
 |
Among the Living by Anthrax If Metallica and Slayer invented speed metal, Anthrax brought it to the East Coast and imbued it with the attitude and excitement of New York hardcore. Among the Living is, without a doubt, their finest hour--a roaring, adrenaline-pumped collection of flailing beats, precise, razor-edged riffs and shout-along refrains. Unlike most full-throttle metal vocalists of the era, Joey Belladonna chose to sing as well as shout, giving songs like "Among the Living," "Indians" and "Efilnikcufecin" ("nice fuckin' life" spelled backwards) a decided melodic edge. Yet Scott Ian and Dan Spitz's buzzsaw guitar flurries, and Charlie Benante's insistent drumming, prevented the songs from ever degenerating into the run-of-the-mill heavy metal they so despised. --Jon Wiederhorn |
 |
N.F.V.: Oidivnikufesin Starring: Anthrax Region 0 NTSC. A full show from rock Legends Anthrax recorded at the Hammersmith Odeon London during their UK tour of 1987.Both the band and individual members have made many, many TV appearances across famous US shows and in the UK they became well known partly for this legendary concert shot in November 1987 at the Hammersmith Odeon |
 |
Spreading the Disease by Anthrax |
|
Bring The Noise by Island Records | |
 |
Anthrax - 80's Cartoon T-Shirt - Ships in ''24'' Hours!, Size: X-Large Anthrax - 80's Cartoon T-Shirt |
 |
State of Euphoria by Anthrax |
 |
Alive 2: The DVD Starring: Anthrax Studio: Uni Dist Corp (music) Release Date: 09/20/2005 |
 |
Persistence of Time by Anthrax |
 |
Persistence Of Time by Island Records |
 |
Anthrax: Anthrology: No Hit Wonders 1985-1991 by Anthrax |
| © 2009 BrightSurf.com |